The Uriach pharmaceutical group has completed the remodeling of its corporate bodies, with the separation of the owners' council, where members of the founding family sit, and the administration council, with a majority outside the family. Sources close to the company explained that the remodeling "rejuvenates the board and prepares it for the next stage of the company, which is entering more countries and will be structured as a multinational."
With the remodeling, the board of owners chaired by Enrique Uriach Torelló is made up of the company's honorary president, Juan Uriach Marsal, his five sons and Joaquim Agut, Cirsa's executive president, who until now was part of the board of directors. This organ, chaired by Luís Cantarell since last year, has incorporated Guillermo Quintero, member of the sixth generation of the family; Montse Muñoz, vice-president of Danone and director of Grifols; and Carlos Muñoz, president of Volotea. Enrique and Joaquín Uriach Torelló and the CEO, Oriol Segarra, are also part of the board of directors.
Uriach sold its drug division a year ago to focus on designing and marketing self-care products. In 2021, the group had a turnover of 253 million euros in this business, with an operating profit or EBITDA of 38 million euros. The group's plans foresee reaching a turnover of 450-500 million euros in 2025, with between 80 and 100 million Ebitda, with acquisitions and its own organic growth, which would make it one of the European leaders in the sector.